MABE333
Anti-N-Myc Antibody, clone NCM II 100
clone NCM II 100, from mouse
Sign Into View Organizational & Contract Pricing
All Photos(1)
N-myc proto-oncogene protein, Class E basic helix-loop-helix protein 37, bHLHe37
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
NCM II 100, monoclonal
species reactivity
human
technique(s)
immunocytochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgG1κ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... MYCN(4613)
General description
The v-myc oncogene, initially identified in the MC29 avian retrovirus, causes myelocytomas, carcinomas, sarcomas and lymphomas, and belongs to a family of oncogenes conserved throughout evolution. In humans the family consists of five genes: c-myc, N-myc, R-myc, L-myc and B-myc. Amplification of the N-myc gene has been found in human neuroblastomas and cell lines. The extent of N-myc amplification correlates well with the stage of neuroblastoma disease. Immunological studies have shown that the human N-myc gene gives rise to at least two nuclear phosphoproteins that exhibit relatively short (30 min) half lives in vivo and exhibit DNA binding properties in vitro.
Immunogen
Recombinant protein corresponding to human N-Myc.
Application
Immunofluorescence Analysis: A representative lot from an independent laboratory detected N-Myc in IMR5 cells (Ikegaki, N., et al. (1986). 83(16):5929-5933.).
Immunoprecipitation Analysis: A representative lot from an independent laboratory immunoprecipitated N-Myc in IP (Brondyk, W. H., et al. (1991). 6(7):1269-1276.).
Immunoprecipitation Analysis: A representative lot from an independent laboratory immunoprecipitated N-Myc in IP (Brondyk, W. H., et al. (1991). 6(7):1269-1276.).
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Transcription Factors
Transcription Factors
Use Anti-N-Myc Antibody, clone NCM II 100 (mouse monoclonal antibody) validated in WB, IP, ICC to detect N-Myc also known as N-myc proto-oncogene protein, Class E basic helix-loop-helix protein 37, bHLHe37.
Quality
Evaluated by Western Blot in IMR-32 cell lysate.
Western Blot Analysis: 0.5 µg/mL of this antibody detected N-Myc in 10 µg of IMR-32 cell lysate.
Western Blot Analysis: 0.5 µg/mL of this antibody detected N-Myc in 10 µg of IMR-32 cell lysate.
Target description
~55 kDa observed. Uniprot describes a molecular weight at ~50 kDa Uniprot states that this protein may be phosphorylated.
Physical form
Format: Purified
Protein G Purified
Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Analysis Note
Control
IMR-32 cell lysate
IMR-32 cell lysate
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Scientific reports, 13(1), 16443-16443 (2023-10-01)
Neuroblastoma, the most common type of pediatric extracranial solid tumor, causes 10% of childhood cancer deaths. Despite intensive multimodal treatment, the outcomes of high-risk neuroblastoma remain poor. We urgently need to develop new therapies with safe long-term toxicity profiles for
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(29), 3217-3228 (2021-06-11)
Clinical outcomes of patients with neuroblastoma range from spontaneous tumor regression to fatality. Hence, understanding the mechanisms that cause tumor progression is crucial for the treatment of patients. In this study, we show that FOXR2 activation identifies a subset of
Cancer cell, 36(1), 51-67 (2019-07-10)
Embryonal tumors with multilayered rosettes (ETMRs) are highly lethal infant brain cancers with characteristic amplification of Chr19q13.41 miRNA cluster (C19MC) and enrichment of pluripotency factor LIN28A. Here we investigated C19MC oncogenic mechanisms and discovered a C19MC-LIN28A-MYCN circuit fueled by multiple
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service